Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Dose-escalated brachytherapy best treatment for unfavourable-risk localised prostate cancer

2015 Genitourinary Cancers Symposium

26 - 28 Feb 2015

Published: 26 Feb 2015

Views: 2933

Rating:

Save

Dr Scott Tyldesley - British Columbia Cancer Agency, Vancouver, Canada

Dr Tyldesley talks to ecancertv at ASCO GU 2015 about his work looking at dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) to treat men with unfavourable-risk localised prostate cancer.

Related Videos

Understanding the use of PARPi combinations to treat patients with mCRPC

Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof...

Understanding the use of PARPi combinations to treat patients with mCRPC ( Prof Axel Merseburger, Dr Friederike Schlurmann, Dr Elena Castro and Prof Gerhardt Attard )

Adjuvant radiotherapy has no benefit following radical prostatectomy

Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK

Adjuvant radiotherapy has no benefit following radical prostatectomy ( Prof Noel Clarke - The Christie NHS Foundation Trust, Manchester, UK )

Management of prostate cancer in Africa: Looking to the future

Dr Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA

Management of prostate cancer in Africa: Looking to the future ( Dr Timothy Rebbeck - Dana-Farber Cancer Institute, Boston, USA )

A single fractionated cycle of 225Ac-J591 shows preliminary efficacy on mCRPC...

Dr Jones Nauseef - Weill Cornell Medicine, New York City, USA

$A single fractionated cycle of 225Ac-J591 shows preliminary efficacy on mCRPC patients ( Dr Jones Nauseef - Weill Cornell Medicine, New York City, USA )$

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy...

Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC ( Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia )

Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free...

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany

Complete biochemical response below 0.1 ng/ml predicts long-term therapy-free survival via PSMA-radioguided surgery ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )

ASCO GU 2023: Latest updates in mRCC

Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor...

ASCO GU 2023: Latest updates in mRCC ( Dr Javier Puente, Dr Bernard Escudier, Prof Stéphane Oudard, Prof Viktor Grünwald and Prof Toni Choueiri )

Hypofractionated high dose intensity modulated radiotherapy non-inferior for...

Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK

$Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer ( Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK )$

Stereotactic body radiotherapy compared with surgery for localised prostate...

Dr Nicholas John van As - The Royal Marsden NHS Foundation Trust, London, UK

Stereotactic body radiotherapy compared with surgery for localised prostate cancer ( Dr Nicholas John van As - The Royal Marsden NHS Foundation Trust, London, UK )

More from ecancer